期刊文献+

人甲型H7N9禽流感全病毒灭活疫苗在小鼠中的免疫原性 被引量:4

Immunogenicity of inactivated human avian influenza A H7N9 virus vaccine in mice
原文传递
导出
摘要 目的评价人甲型H7N9禽流感全病毒灭活疫苗在小鼠中的免疫原性。方法分别将H7N9与H1N1、H5N1全病毒灭活疫苗稀释至血凝素抗原(hemagglutinin,HA)浓度分别为30、6、1.2、0.24和0.048μg/ml后,免疫BALB/c小鼠,各10只,0.5 ml/只,采用血凝抑制(hemagglutinin inhibition,HI)试验检测免疫后小鼠血清抗体滴度,计算抗体几何平均滴度(GMT)及半数有效剂量(ED_(50)),并检测免疫后小鼠血清对其他亚型病毒的HI滴度。结果 H7N9组小鼠阳转率与H1N1组较相近,仅H7N9 0.6μg剂量组GMT明显低于H1N1同剂量组(P<0.001),其余剂量组差异无统计学意义(P>0.05);H7N9与H1N1、H5N1全病毒灭活疫苗免疫小鼠ED_(50)分别为0.27、0.12和15μg HA。免疫后血清对其他亚型病毒无交叉反应。结论 H7N9疫苗在小鼠中的免疫原性略低于H1N1疫苗,但明显优于H5N1疫苗。 Objective To evaluate the immunogenicity of inactivated human avian influenza A H7N9 vaccine in mice.Methods Inactivated whole influenza virus H7N9,H1N1 and H5N1 vaccines were diluted to hemagglutinin(HA)concentrations of 30,6,1.2,0.24 and 0.048 μg / ml separately,with which BALB / c mice were immunized,0.5 ml for each.The serum antibody titers of mice were determined by hemagglutinin inhibition(HI)test,based on which GMT and median effective dose(ED50)was calculated,and the HI titer of murine sera against influenza virus of other subtypes were determined.Results The positive conversion rate of antibody of mice in H7N9 group was similar to that in H1N1 group.The GMTs of mice immunized with 0.6 μg H7N9 virus were significantly lower than(P〈.001),while those at other dosages showed no significant difference with(P〈.05),those of mice immunized with H1N1 virus at the same dosages.The ED50 of inactivated H7N9,H1N1 and H5N1 virus vaccines in mice were 0.27,0.12 and 15 μg HA respectively.The immunosera showed no cross-reaction with virus of other subtypes.Conclusion The immunogenicity of inactivated H7N9 vaccine in mice was slightly lower than that of H1N1 vaccine,while was significantly higher than that of H5N1 vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2016年第5期455-457,共3页 Chinese Journal of Biologicals
基金 国家国际科技合作与交流专项(2013DFA31680)
关键词 H7N9 流感疫苗 小鼠 免疫原性 H7N9 Influenza vaccine Mouse Immunogenicity
  • 相关文献

参考文献5

二级参考文献16

  • 1顾琴,李娟,徐康维,邵铭,廖国阳,李卫东,李长贵.流感疫苗单向免疫扩散试验中抗血清制备新方法的研究[J].微生物学免疫学进展,2011,39(4):8-12. 被引量:1
  • 2黄艳.H_5N_1灭活全病毒佐剂疫苗的安全性和免疫原性:Ⅰ期随机对照试验[J].中国处方药,2006,5(11):49-49. 被引量:25
  • 3朱智勇,丁晓航,朱函坪,李岩金,陈学奎,沈吉友,张涛,何培江,姚苹苹,徐芳,翁景清,谢荣辉,赵芝雅,龚华岳,郭志宏,苏波,孙淑滨,梁伟峰.人用H5N1禽流感裂解疫苗的制备工艺[J].中国生物制品学杂志,2007,20(7):503-506. 被引量:3
  • 4国家药典委员会.中国药典[S].三部.北京:中国医药科技出版社,2010:附录Ⅵ B.
  • 5Authier FJ, Gherardi RK. Safety and immunogenicity of H5N1 vaccine [J]. Lancet, 2006, 368 (9554): 2209-2210.
  • 6The World Health Organization Global Influenza Program Surveill ance Network: Evolution of H5N1 avian influenza viruses in Asia [J]. Emerg Infect Dis, 2005, 11 (10): 1515-1521.
  • 7Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza [J]. Nat Rev Microbiol, 2004, 2 (10): 842-847.
  • 8WHO. Development and evaluation of influenza pandemic vac- cines: report of WHO expert meeting. Initiative for Vaccine Re- search, Global Influenza Prograrame [OL]. (2006-08-17)[2011-02- 18]. http://www.who.int / vaccine_research / documents / Report 20021105.pdf( accessed Aug 17, 2006 ).
  • 9WHO. Responding to the avian influenza pandemic threat :recom- mended strategic actions [ OL ]. (2006-08-17 ) [ 2011-02-18]. http:// www.who.int / csr / resources / publications / influenza / WHO_CDS_CSR_GIP_05_8-EN.pdf(accessed Aug 17, 2006).
  • 10World Health Organization Expert Committee on Biological Standardization. Proposed guidelines on regulatory preparedness for human pandemic influenza vaccines[OL]. 2007. http://www. who. intlvaccine_ research/diseasesiinfluenzaiGuidelines _ regulatory_ preparedness_pandemic_influenza_ vaccines. pdf.

共引文献391

同被引文献9

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部